Systemic immunosuppressive therapies for uveitis in developing countries
There are multiple approaches to inhibit inflammatory molecules and pathways in noninfectious uveitis. The cornerstone of local and systemic anti-inflammatory treatment is corticosteroid therapy. Corticosteroids remain the most potent and efficacious drugs for treating intraocular inflammation. However, their long-term use is limited by their medium- and long-term side effects, which are a major concern. The approach taken to limit corticosteroid side effects is to introduce steroid-sparing agents that suppress the inflammatory pathways and immune response differently than corticosteroids. There are several classes of such drugs that are affordable, effective, and generally well-tolerated. Relatively recently, an increasing range of biologic agents has become available to treat intraocular inflammation. However, the relatively expensive cost of these therapies limits their use in the developing world. This systemic review aimst to discuss the use of corticosteroids and different immunosuppressive regimens in the management of various uveitides.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
---|---|
Enthalten in: |
Indian journal of ophthalmology - 68(2020), 9 vom: 01. Sept., Seite 1852-1862 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Agrawal, Hitesh [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenal Cortex Hormones |
---|
Anmerkungen: |
Date Completed 14.05.2021 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.4103/ijo.IJO_1548_20 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM313971234 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM313971234 | ||
003 | DE-627 | ||
005 | 20231225151725.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4103/ijo.IJO_1548_20 |2 doi | |
028 | 5 | 2 | |a pubmed24n1046.xml |
035 | |a (DE-627)NLM313971234 | ||
035 | |a (NLM)32823402 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Agrawal, Hitesh |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systemic immunosuppressive therapies for uveitis in developing countries |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.05.2021 | ||
500 | |a Date Revised 04.12.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a There are multiple approaches to inhibit inflammatory molecules and pathways in noninfectious uveitis. The cornerstone of local and systemic anti-inflammatory treatment is corticosteroid therapy. Corticosteroids remain the most potent and efficacious drugs for treating intraocular inflammation. However, their long-term use is limited by their medium- and long-term side effects, which are a major concern. The approach taken to limit corticosteroid side effects is to introduce steroid-sparing agents that suppress the inflammatory pathways and immune response differently than corticosteroids. There are several classes of such drugs that are affordable, effective, and generally well-tolerated. Relatively recently, an increasing range of biologic agents has become available to treat intraocular inflammation. However, the relatively expensive cost of these therapies limits their use in the developing world. This systemic review aimst to discuss the use of corticosteroids and different immunosuppressive regimens in the management of various uveitides | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Biologicals | |
650 | 4 | |a corticosteroids | |
650 | 4 | |a immunosuppression | |
650 | 4 | |a inflammation | |
650 | 4 | |a non infectious uveitis | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
700 | 1 | |a Doan, Hien |e verfasserin |4 aut | |
700 | 1 | |a Pham, Brandon |e verfasserin |4 aut | |
700 | 1 | |a Khosla, Amit |e verfasserin |4 aut | |
700 | 1 | |a Babu, Manohar |e verfasserin |4 aut | |
700 | 1 | |a McCluskey, Peter |e verfasserin |4 aut | |
700 | 1 | |a Nguyen, Quan Dong |e verfasserin |4 aut | |
700 | 1 | |a Sangwan, Virender |e verfasserin |4 aut | |
700 | 1 | |a Reddy, Subhakar |e verfasserin |4 aut | |
700 | 1 | |a Sawhney, Sujata |e verfasserin |4 aut | |
700 | 1 | |a Tyagi, Mudit |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Indian journal of ophthalmology |d 1971 |g 68(2020), 9 vom: 01. Sept., Seite 1852-1862 |w (DE-627)NLM000735493 |x 1998-3689 |7 nnns |
773 | 1 | 8 | |g volume:68 |g year:2020 |g number:9 |g day:01 |g month:09 |g pages:1852-1862 |
856 | 4 | 0 | |u http://dx.doi.org/10.4103/ijo.IJO_1548_20 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 68 |j 2020 |e 9 |b 01 |c 09 |h 1852-1862 |